Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma

Trial Profile

Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma

Suspended
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs AR 42 (Primary) ; Pazopanib (Primary)
  • Indications Renal cell carcinoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Mar 2017 Planned End Date changed from 1 Jun 2025 to 30 Jun 2025.
    • 03 Mar 2017 Planned primary completion date changed from 1 Mar 2019 to 30 Mar 2019.
    • 22 Nov 2016 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top